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Abstract
R-spondins (Rspos) comprise a family of four secreted proteins that have important roles in cell proliferation, cell fate
determination and organogenesis. Rspos typically exert their effects by potentiating the Wnt/b-catenin signaling pathway.
To systematically investigate the impact of Rspo/Wnt on gene expression, we performed a microarray analysis using C57MG
mouse mammary epithelial cells treated with recombinant Rspo2 and/or Wnt3a. We observed the up- and down-regulation
of several previously unidentified target genes, including ones that encode proteins involved in immune responses,
effectors of other growth factor signaling pathways and transcription factors. Dozens of these changes were validated by
quantitative real time RT-PCR. Time course experiments showed that Rspo2 typically had little or no effect on Wnt-
dependent gene expression at 3 or 6 h, but enhanced expression at 24 h, consistent with biochemical data indicating that
Rspo2 acts primarily to sustain rather than acutely increase Wnt pathway activation. Up-regulation of gene expression was
inhibited by pre-treatment with Dickkopf1, a Wnt/b-catenin pathway antagonist, and by siRNA knockdown of b-catenin
expression. While Dickkopf1 blocked Rspo2/Wnt3a-dependent down-regulation, a number of down-regulated genes were
not affected by b-catenin knockdown, suggesting that in these instances down-regulation was mediated by a b-catenin-
independent mechanism.
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Introduction
The R-spondin (Rspo) protein family consists of four homolo-
gous members that are dynamically expressed during embryogen-
esis and have important roles in development [1–5]. Rspo2
participates in myogenesis, limb, laryngeal-tracheal and lung
morphogenesis, osteoblast maturation and bone mineralization
[4,6–9], while Rspo3 is required for placental formation, angioblast
and vascular development [10,11]. Mutations in particular Rspo
genes cause human syndromes characterized by specific birth
defects. For example, loss-of-function Rspo1 mutations result in
female-to-male gender reversal due to aberrant ovarian develop-
ment [12], and Rspo4 point mutations are associated with absent or
malformed fingernails and toenails (anonychia) [13,14].
Several lines of evidence have linked Rspos to the Wnt genes.
The Wnts comprise a large family of secreted, lipid-modified
glycoproteins that have a variety of crucial functions during
embryonic development and contribute to tissue homeostasis in
the adult [15–17]. Rspo and Wnt genes exhibit overlapping patterns
of expression in many tissues during development, including the
neural tube and muscle [2–4]. Together they induce myogenesis
by stimulating the transcriptional activity of b-catenin [4], a key
mediator of Wnt signaling that promotes differentiation or
proliferation depending on the context [16]. Administration of
Rspo protein to mice elicited a massive proliferative expansion of
the small intestines, consistent with a direct effect on Wnt/b-
catenin signaling in the crypts [18]. Recombinant Rspo supports
the propagation of intestinal crypt and villus structures in three-
dimensional ex vivo cultures [19]. Activation of the b-catenin
pathway requires Wnt binding to receptors in the Frizzled family
and co-receptors, low density lipoprotein receptor-related proteins
5 or 6 (LRP5/6). These interactions trigger phosphorylation of
LRP5/6 and disassembly of a b-catenin degradation complex,
which allows b-catenin to accumulate in the cytosol and
translocate to the nucleus where it functions as a transcriptional
co-activator [20,21]. How Rspos enhance signaling through this
pathway is uncertain. Reports vary regarding the ability of Rspos
to bind Frizzleds, LRP6 or Wnts [22,23]. One group suggested
that Rspos inhibit LRP6 internalization and down-regulation
[24,25], although others disputed this mechanism [26–28]. Recent
articles claim that LGR4/5/6 (leucine-rich repeat containing G
protein-coupled receptor) function as Rspo receptors and regulate
Wnt/b-catenin signaling through association with Wnt receptors
[29–31].
The connection between Wnt and Rspo extends to cancer.
Wnt1 was identified as a gene that was insertionally activated by
the mouse mammary tumor virus (MMTV) [32,33], and
subsequently shown to stimulate the formation of adenocarcino-
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[34]. Expression of Rspo2 and other Rspo family members also was
induced by insertion of MMTV into mammary epithelial cell
DNA, and similarly associated with tumorigenesis [35,36].
Interestingly, activation of Rspo genes in MMTV-derived tumors
was accompanied by independent activation of Wnt or Fgf genes,
with Rspo2 and Wnt3a expression being the most frequent
combination [35]. Moreover, our recent study suggested that
Rspos and Wnts cooperate to promote malignant transformation
and/or influence tumor behavior of mammary cells [37].
Considering the well-established role of Wnt/b-catenin signaling
in several types of cancer [15–17], stimulation of tumorigenesis via
this pathway would not be surprising. However, other Wnt
pathways also contribute to neoplasia [38,39] and Rspo3 was
recently shown to activate JNK signaling [40], suggesting that the
proposed cooperation of Rspos and Wnts in cancer might involve
other mechanisms as well.
The present study was undertaken to investigate the interaction
of Rspo and Wnt in mammary epithelial cells with a primary focus
on the regulation of gene expression. We used the C57MG mouse
mammary epithelial line as our model system because several
earlier reports had characterized Wnt target genes in this setting
[41–46], facilitating our analysis of Rspo effects on Wnt-dependent
gene expression. In contrast to previous studies that relied on the
use of crude Wnt-containing conditioned medium or C57MG cells
transfected with Wnt cDNA, we used purified recombinant
proteins, Rspo2 and Wnt3a, thus ensuring the specificity of
elicited responses and enabling time-course and dose-response
experiments. Our investigation revealed the up-regulation and
down-regulation of many novel Wnt target genes, which often was
enhanced by concomitant Rspo2 addition. Typically up-regulation
was mediated by b-catenin, as indicated by inhibition with small
interfering RNA (siRNA) that blocked b-catenin expression and
the Wnt/b-catenin pathway antagonist Dickkopf 1 (Dkk1) [47].
Interestingly, Dkk1 also inhibited the down-regulation of Wnt3a/
Rspo2 target genes, but only a subset of these decreases in
expression was disrupted by knockdown of b-catenin. This
suggested that b-catenin-independent mechanisms elicited by
Wnt3a and Rspo2 also control gene expression in mammary
epithelial cells.
Results and Discussion
Microarray analysis of Rspo2/Wnt3a-dependent gene
expression in C57MG cells
Initially we monitored the expression of prototypical Wnt target
genes (Axin2, Ccnd1, Msln; for accession numbers of genes
mentioned in this article see Table S2) by quantitative real-time
RT-PCR (qRT-PCR) in time-course and dose-response experi-
ments to optimize conditions for the microarray analysis. Based on
these results, C57MG cells were incubated for 24 h with 100 ng/
ml Rspo2 or Wnt3a alone or in combination, or with the carrier
protein bovine serum albumin (BSA, 16 mg/ml). Total RNA was
harvested from triplicate monolayers corresponding to each
treatment group and analyzed with Agilent’s Whole Mouse
Genome Oligo-4644K microarray, which is comprised of
41,534 60-mer oligonucleotide probes representing over 41,000
transcripts. A total of 22,696 transcripts were detected in the
C57MG cells. Expression of 1100 genes was altered at least two-
fold by Rspo2 and Wnt3a alone or together, relative to the BSA
control (p,0.05). Distinct patterns of expression were associated
with each treatment group as illustrated by a heat map of
differentially expressed genes (Figure 1A). The greatest number of
changes in expression was observed with the combination of
Rspo2 and Wnt3a. Not only were genes up-regulated by Rspo2
plus Wnt3a (Figure 1A, lower portion of heat map), but an even
larger number were down-regulated by this treatment (Figure 1A,
upper and middle portion). Approximately 25% of the affected
genes were up-regulated (Figure 1B) and 75% down-regulated
(Figure 1C) by the recombinant proteins. Rspo2 alone altered the
expression of relatively few genes (14 up-regulated, 90 down-
regulated), and most (90) were affected by Wnt3a as well (Figure 1B
and 1C). While Wnt3a increased the expression of 72 genes and
decreased the expression of 350, an additional 664 transcripts were
only altered by the combination of Rspo2 and Wnt3a (Figure 1B
and 1C). These results reinforced the idea that Rspo2 and Wnt3a
have overlapping and synergistic effects on gene expression.
Characterization of Rspo2/Wnt3a responsive genes according
to gene ontology classification showed a strong correlation with
development (183 genes, P-value 2.06E-09) and signal transduc-
tion (211 genes, P-value 1.08E-06). This was not surprising given
the established association of Rspos and Wnts with these biological
processes. However, the diversity of subcategories within these
groups was noteworthy, implying potential relevance beyond
mammary cell biology and extensive crosstalk with other signaling
pathways (Table S1). Unexpectedly, there was an even stronger
link to genes involved in immune response (89 genes, P-value
1.15E-19), including innate immunity and inflammation (Table
S1). While contributions of Wnt signaling to the development and
function of the immune system have been described [48,49], many
of the immune response genes detected in our microarray analysis
were not previously associated with Wnt or Rspo regulation and
therefore suggest novel mechanisms of immune regulation. In
addition to these gene ontology categories, several putative
Rspo2/Wnt target genes were classified among various metabolic
processes (Table S1). Interestingly, Wnt/b-catenin signaling was
recently reported to control the hepatic expression of genes that
mediate gluconeogenesis [50].
Validation of known and novel target genes
We verified the expression pattern of several dozen genes by
qRT-PCR (Table S2), confirming the reliability of the microarray
analysis. In a few instances the magnitude of change in gene
expression elicited by Rspo2 and/or Wnt3a relative to BSA
differed in qRT-PCR vs. microarray analysis, but the overall
pattern was similar in a large majority of the genes examined. We
observed the up-regulation of several previously identified Wnt/b-
catenin target genes including those encoding Axin2, Ccnd1, Msln,
Ctgf, Efnb2 and Twist1 (Table 1). While the expression of these
genes is mediated by b-catenin/TCF complexes, we also observed
changes that involved b-catenin interactions with other transcrip-
tion factors such as the retinoic acid receptor-dependent, up-
regulation of Enpp2/autotaxin [51]. Of note, many of the changes in
gene expression confirmed in C57MG cells also were verified by
qRT-PCR in another mouse mammary epithelial cell line, NOG-
8 (data not shown). Because the regulation of several previously
documented Wnt target genes was common to cells from other
organs, we suspect that at least some of the new data obtained in
the present microarray analysis are likely to be relevant to other
tissues and cell types. Interestingly, Rspo2 strongly enhanced the
b-catenin-dependent activity of Wnt4 in C57MG cells, which by
itself was low compared to Wnt3a. However, a combination of
Rspo2 and Wnt5a was unable to stimulate Axin2 expression in
C57MG cells, consistent with the general lack of Wnt5a activity in
the b-catenin pathway.
Among the immune response genes confirmed by qRT-PCR
(Table 2), the increase in expression of the chemokine receptor
CXCR6 was of particular interest because of its association with
Novel Target Genes of Rspo2 and Wnt3a
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CXCR6 expression is mediated by HIF1a and contributes to breast
cancer metastasis [55]. HIF1a is another transcription factor that
acts in concert with b-catenin to regulate a set of target genes [56];
perhaps such cooperation controls CXCR6 expression as well. The
striking increase in interleukin 33 (IL33) also was noteworthy.
Although originally associated with T cell activation, IL33
subsequently has been shown to act on a variety of cell types
[57]. In contrast to CXCR6 and IL33, the chemokines CCL5 and
CCL7 were down-regulated by Wnt3a alone and in combination
with Rspo2. Both Rspo2 and Wnt3a inhibited the expression of
several acute phase reactants (Saa3, C3, Hp and Lcn2), in some
instances by .90%. While some changes in expression of immune
response genes such as CXCR6 presumably have a direct effect on
mammary epithelial cells, others might regulate immune function
in the microenvironment. Alternatively, Saa3 expressed by the
bovine mammary gland is transmitted in milk and thought to
facilitate immune function in the offspring [58].
Potential crosstalk between Wnt/Rspo and other growth factor
signaling mechanisms was implicit in the synergistic up-regulation
of multiple genes that participate in insulin/IGF, TGFb and FGF
pathways (Table 3). One of these genes, IRS1, also was identified
as a pathophysiologically relevant Wnt/b-catenin target gene in
colorectal carcinomas [59]. Up-regulation of insulin/IGF pathway
genes, including IGF1, is provocative given the association of IGF
Figure 1. Schematic summary of Rspo2/Wnt3a-dependent gene expression in C57MG cells. (A) Heat map shows genes that were up-
regulated (red) or down-regulated (blue) at least two-fold relative to the normal value (yellow). Microarray analysis was performed with RNA
harvested and processed individually from three monolayers for each treatment group [B=BSA (16 ug/ml); R=Rspo2 (100 ng/ml); W=Wnt3a
(100 ng/ml); R/W=Rspo2 (100 ng/ml) + Wnt3a (100 ng/ml)]. (B) Venn diagram indicates the number of genes that were up-regulated uniquely or in
common by Rspo2, Wnt3a or the combination of both. (C) Venn diagram indicates the number of genes that were down-regulated uniquely or in
common by Rspo2, Wnt3a or the combination of both.
doi:10.1371/journal.pone.0029455.g001
Table 1. Microarray data of known Wnt/b-catenin target
genes validated by qRT-PCR.
Rspo2 Wnt3a Wnt3a/Rspo2
Gene
Fold
change P value
Fold
change P value
Fold
change P value
Axin2 0.75 0.44 1.53 0.17 21.62 0.01
Rhou 0.99 0.96 2.22 0.01 12.78 0.15E-2
Enpp2 0.75 0.19 1.92 0.02 9.21 0.95E-3
Ahr 1.02 0.82 2.1 0.67E-3 7.24 0.90E-3
Klf5 1.45 0.01 2.23 0.34E-2 5.06 0.76E-2
Edn1 1.41 0.01 2.18 0.19E-2 4.22 0.19E-5
Ccnd1 1.39 0.08 2.12 0.02 3.28 0.02
Msln 1.14 0.03 1.82 0.39E-2 2.91 0.23E-4
Ctgf 1.24 0.06 1.84 0.11E-2 2.52 0.67E-3
Efnb2 1.47 0.02 1.82 0.03 2.3 0.13E-2
Twist1 1.19 0.02 1.27 0.09 2.04 0.015
Fold change relative to level in cells treated with BSA.
doi:10.1371/journal.pone.0029455.t001
Table 2. Microarray data of immune response genes
validated by qRT-PCR.
Rspo2 Wnt3a Wnt3a/Rspo2
Gene
Fold
change P value
Fold
change P value
Fold
change P value
IL33 5.11 0.19E-2 11.03 0.22E-2 33.54 0.36E-4
CXCR6 0.74 0.65 2.96 0.04 22.84 0.67E-5
TGFb2 1.11 0.39 1.62 0.09 4.38 0.05
InhbA 1.40 0.06 2.00 0.52E-3 3.74 0.01
TGFbR2 1.03 0.77 1.89 0.05 3.20 0.03
CCL5 0.69 0.05 0.58 0.21E-2 0.38 0.39E-3
IRF7 0.71 0.32E-3 0.40 0.14E-3 0.28 0.11E-2
CCL7 0.40 0.12E-2 0.31 0.15E-2 0.13 0.11E-2
Saa3 0.08 0.18E-2 0.09 0.75E-3 0.11 0.20E-3
C3 0.22 0.10E-3 0.12 0.39E-3 0.06 0.40E-3
Hp 0.16 0.11E-2 0.02 0.53E-2 0.03 0.51E-2
Lcn2 0.05 0.31E-2 0.02 0.29E-2 0.01 0.29E-2
Fold change relative to level in cells treated with BSA.
doi:10.1371/journal.pone.0029455.t002
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interactions between Wnt and TGFb or Wnt and FGF signaling
[61,62]. The present data extend these observations by suggesting
that Wnt/Rspo signaling regulates the expression of various
effectors in these growth factor pathways.
We verified that Rspo2 and/or Wnt3a controlled the expression
of several transcription factors (Table 4). Klf5 had been identified
as a Wnt target gene in multiple settings including C57MG cells
[45,46], while the up-regulation of Helt was a novel finding as was
the down-regulation of Klf15, IRF7 and Stat1 (Table 4). Many
other confirmed, previously unrecognized Wnt target genes are
listed in Table 5. Included in this group are genes encoding the
tyrosine kinases HCK and Tec, angiopoietin1 and angiopoietin-
like4, and inscuteable, a mediator of cell polarity.
Induction of the aryl hydrocarbon receptor (Ahr) by Wnt3a and
Rspo2 was especially noteworthy. Though described as a Wnt
target gene in a few prostate carcinoma lines [63], this relationship
had not been noted elsewhere. Ahr was first identified as the
dioxane receptor and associated with its carcinogenic and other
toxic effects. Subsequently Ahr was recognized as a transcription
factor that bound endogenous or xenobiotic ligands and hetero-
dimerized with Arnt/HIF2 to activate the expression of genes such
as Cyp1a1 [64]. More recently Ahr was shown to function as an
E3 ubiquitin ligase that targeted the estrogen and androgen
receptors for degradation [65,66], an activity that might be
exploited in cancer therapy [67,68]. Remarkably, Ahr also serves
as an E3 ubiquitin ligase for b-catenin and treatment with natural
Ahr ligands suppressed intestinal carcinogenesis in Apc
Min/+ mice
[69]. This implied that the up-regulation of Ahr could provide a
mechanism to suppress tumorigenesis by administering Ahr
ligands. Such an approach might be useful for the treatment
and/or chemoprevention of colorectal, breast and perhaps other
cancers. Conversely, Ahr ligand stimulated the expression of Rspo1
in a zebrafish model of regenerating fin, and thereby enhanced
Wnt/b-catenin signaling [70]. Other recent articles have described
an interplay of Ahr and Wnt/b-catenin signaling that results in
either increase or decrease in target gene expression [71,72]. It
appears that the ability of Ahr to promote or impede b-catenin
transcriptional activity is context-specific.
Rspo2 promotes Wnt3a-dependent gene expression by
prolonging b-catenin pathway activation
Time-course experiments with recombinant Wnt3a indicated
that gene expression typically was increased at 3 h, reached a peak
at 6 h and was reduced at 24 h (Figure 2A). Rspo2 had minor
effects on its own or with Wnt3a at 3 and 6 h, but it markedly
enhanced expression of transcript at 24 h (Figure 2A). Though
stimulation was not as dramatic at the protein level, immunoblot
analysis confirmed the up-regulation of Klf5 and Ahr, with the
effect of Rspo2 evident at 24 h (Figure 2B). The doublet bands in
the Klf5 blot probably reflected differential post-translational
modification, which had been previously described [73]. Similar
observations about the timing of responses to Rspo2 and Wnt3a
were made with standard biochemical readouts of b-catenin
pathway activation. Rspo2 alone elicited only a small increase in
Table 3. Microarray data of genes in other growth factor
signaling pathways.
Rspo2 Wnt3a Wnt3a/Rspo2
Gene
Fold
change P value
Fold
change P value
Fold
change P value
IGFbp2 0.99 0.98 2.64 0.02 8.82 0.57E-2
TGFb2 1.11 0.39 1.62 0.09 4.38 0.05
Spry1 1.64 0.49E-2 2.42 0.21E-3 4.20 0.42E-4
IGF1 1.31 0.28 2.04 0.53E-2 3.21 0.81E-2
TGFbR2 1.03 0.77 1.89 0.05 3.20 0.03
IRS1 1.08 0.53 1.71 0.67E-2 3.06 0.17E-2
FGFR5 1.08 0.27 1.17 0.45 2.47 0.54E-2
FGF21 1.43 0.32 2.35 0.48E-2 2.37 0.07
Fold change relative to level in cells treated with BSA.
doi:10.1371/journal.pone.0029455.t003
Table 4. Microarray data of transcription factor genes
validated by qRT-PCR.
Rspo2 Wnt3a Wnt3a/Rspo2
Gene
Fold
change P value
Fold
change P value
Fold
change P value
Helt 1.48 0.97 2.97 0.31E-2 7.80 0.16E-2
Ahr 1.02 0.82 2.10 0.67E-3 7.24 0.89E-3
Klf5 1.45 0.01 2.23 0.34E-2 5.06 0.76E-2
TCF4 1.29 0.59E-2 1.39 0.01 2.20 0.01
Nanog 2.05 0.73E-2 1.88 0.02 2.18 0.45E-2
Klf15 0.50 0.01 0.43 0.33E-2 0.30 0.39E-3
IRF7 0.71 0.32E-3 0.40 0.14E-3 0.28 0.11E-2
Stat1 0.50 0.04 0.31 0.02 0.22 0.02
Fold change relative to level in cells treated with BSA.
doi:10.1371/journal.pone.0029455.t004
Table 5. Microarray data of additional novel target genes
validated by qRT-PCR.
Rspo2 Wnt3a Wnt3a/Rspo2
Gene
Fold
change P value
Fold
change P value
Fold
change P value
PpFibp2 1.52 0.07 4.30 0.88E-2 16.34 0.12E-2
HCK 1.13 0.79 3.49 0.02 13.46 0.97E-2
Tspan18 0.90 0.77 1.56 0.16 12.19 0.27E-4
Tec 0.93 0.68 2.68 0.03 11.54 0.29E-2
Chrna1 1.32 0.42 1.94 0.13 6.29 0.79E-2
Klhl30 1.66 0.17 2.23 0.43E-3 6.13 0.41E-5
Insc 1.55 0.13E-2 2.79 0.35E-3 5.64 0.12E-2
Epac1 0.92 0.26 2.71 0.01 4.83 0.12E-5
Itgbl1 2.15 0.06 2.59 0.91E-2 4.45 0.54E-3
FHL1 1.34 0.09 2.48 0.01 3.26 0.31E-2
Wnt9a 1.16 0.52 1.48 0.15 2.97 0.21E-2
Rnd3 1.15 0.39E-2 1.33 0.02 2.33 0.21E-2
Sox9 1.14 0.19 0.66 0.08 0.42 0.31E-2
Angptl4 0.43 0.04 0.25 0.01 0.33 0.01
Smoc1 0.97 0.76 0.59 0.03 0.26 0.34E-2
Angpt1 0.89 0.18 0.42 0.80E-3 0.17 0.17E-2
Fold change relative to level in cells treated with BSA.
doi:10.1371/journal.pone.0029455.t005
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protein (Figure 3). However, Rspo2 enhanced the activity of
Wnt3a in these assays at 24 h (Figure 3). These results
demonstrated that the addition of Rspo2 to Wnt3a caused a
more sustained activation of the b-catenin pathway, reinforcing
our findings with HEK293/STF cells and a truncated Rspo2
derivative [28].
Proof that the b-catenin pathway was responsible for the up-
regulation of validated target genes came from experiments
involving Dkk1, an antagonist of this pathway, and small
interfering RNA knockdown of Ctnnb1 (siCtnnb1), the gene
encoding b-catenin. Pre-treatment of C57MG cells with
recombinant Dkk1 inhibited the stabilization of b-catenin
protein (Figure 4A) and blocked the up-regulation of genes
induced by the combination of Rspo2 (10 ng/ml) and Wnt3a
(100 ng/ml) (Figure 4B–4D and Table S3). Targeting expres-
sion with siCtnnb1 decreased the amount of b-catenin protein
in the absence of growth factor and blocked its accumulation in
response to Rspo2 plus Wnt3a (Figure 5A). As with Dkk1, b-
catenin knockdown disrupted the induction of Axin2, Ahr and
CXCR6 mRNA (Figure 5B–5D) as well as other gene
transcripts (Table S4). Similar results were obtained with two
independent siCtnnb1 reagents (data not shown). Taken
together, these data established that the up-regulation of
Rspo2/Wnt3a target genes was mediated by the b-catenin
pathway and Rspo2 potentiated expression by extending the
duration of pathway activation.
Down-regulation of genes by Wnt3a is rapid, Dkk1-
sensitive and occurs via either a b-catenin-dependent or
-independent mechanism
Time-course analysis of genes down-regulated by Wnt3a and
Rspo2 showed that responses were evident at 3 h and sometimes
even at 1 h, with maximal or near maximal inhibition seen at 6 h
(Figure 6). In general, the effect of Rspo2 plus Wnt3a was not
much stronger than that of Wnt3a alone, although Rspo2 alone
often had significant inhibitory activity. It is possible that the
inhibitory effect of Rspo2 was dependent on low levels of
endogenous Wnt expression, while Wnt3a at 100 ng/ml was
sufficient for a near-maximal effect. As with the up-regulated
genes, pre-treatment of C57MG cells with Dkk1 blocked much if
not all of the Rspo2/Wnt3a activity in the qRT-PCR analysis
(Figure 7A and Table S3). However, b-catenin knockdown only
disrupted the down-regulation of two genes analyzed, Angpt1 and
Smoc1, while having little effect on the others (Figure 7B and
Figure 2. Time-course of Rspo2- and Wnt3a-dependent gene up-regulation in C57MG cells. (A) Quantitative RT-PCR analysis of specific
gene expression in response to Rspo2 (100 ng/ml) alone (blue), Wnt3a (100 ng/ml) alone (green) or the two together (red) at the indicated time
points. Data are the means +/2 S.D. (error bars, sometimes too small to see) of triplicate measurements from one of several experiments with similar
results. (B) Immunoblot analysis of Klf5 and Ahr protein expression following treatment with BSA carrier, Rspo2 (100 ng/ml), Wnt3a (100 ng/ml) alone
or in combination for the indicated periods. Membranes were re-probed for Hsp70 as a loading control.
doi:10.1371/journal.pone.0029455.g002
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treated with Rspo2 or Wnt3a alone (data not shown). These
results implied that b-catenin was not involved in the down-
regulation of most genes identified as Rspo2/Wnt targets in this
study.
Typically Wnt-dependent, b-catenin-mediated gene expres-
sion has been associated with stimulation of gene expression.
These effects require interaction with other transcription factors
such as the DNA-binding TCF family members, as well as
retinoic acid receptor, vitamin D receptor or HIF1a [15–
17,42,51,56,74]. Relatively little is known about the mechanisms
responsible for the down-regulation of gene expression by Wnts
and/or b-catenin. There is one report indicating that Wnt/b-
catenin suppression of N-Acetylglucosaminyltransferase III
expression is associated with TCF binding sites in the promoter
region [75].
Particularly intriguing was the observation that most of the
decreases in gene expression induced by Rspo2/Wnt3a were
Dkk1-sensitive and yet b-catenin-independent. While we cannot
exclude the possibility that residual low levels of b-catenin
following siCtnnb1 treatment had participated in the inhibitory
process, these results suggest that Dkk1 might function in a
manner that does not involve a decline in b-catenin protein levels.
We were unable to ascertain whether LRP5/6 were required for
the de-repression of gene expression by Dkk1 because repeated
efforts to simultaneously knockdown expression of LRP5/6 in
C57MG cells were unsuccessful. Thus, the present results raise the
possibility that the effects of Dkk1 on the suppression of gene
Figure 3. Time-course of Rspo2- and Wnt3a-dependent LRP5/6 phosphorylation and b-catenin stabilization. C57MG cells were treated
with BSA, Rspo2 (100 ng/ml), Wnt3a (100 ng/ml) alone or in combination for the indicated periods. Cell lysates (30 mg protein/lane) were
immunoblotted for phosphorylated LRP5/6, total LRP5, total LRP6 and Hsp70, the latter serving as a loading control. Soluble b-catenin was measured
by immunoblotting after pull-down with GST-E-cadherin.
doi:10.1371/journal.pone.0029455.g003
Figure 4. Dkk1 inhibited up-regulation of genes by Rspo2 and Wnt3a. (A) Immunoblot analysis of total b-catenin (cell lysate, 30 mg protein/
lane) and soluble b-catenin (GST-E-cadherin pull-down) from C57MG cells incubated for 3 h with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml),
with or without 20 min Dkk1 (1 mg/ml) pre-treatment. Western blot of Hsp70 was loading control. (B–D) Quantitative PCR analysis of Axin2, Ahr and
CXCR6 expression by C57MG cells after 24 h incubation with BSA or Rspo2 plus Wnt3a, with or without Dkk1 pre-treatment [experiment performed in
parallel with (A), using the same reagent concentrations]. Results are means +/2 S.D. of triplicate measurements from one of four representative
experiments.
doi:10.1371/journal.pone.0029455.g004
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distinct from disruption of the canonical Wnt/b-catenin pathway.
Elucidation of the mechanisms responsible for Rspo2/Wnt3a-
dependent decreases in gene expression and the manner in which
the decreases were blocked by Dkk1 should be provocative areas
for future research.
Materials and Methods
Reagents
Recombinant mouse Wnt3a (cat. no. 1324-WN), human R-
spondin2 (cat. no. 3266-RS), mouse Dkk1 (cat. no. 5897-DK),
mouse Wnt4 (cat. No. 475-WN) and mouse Wnt5a (cat. No. 645-
Figure 5. Knockdown of b-catenin inhibited up-regulation of genes by Rspo2 and Wnt3a. (A) C57MG cells were pre-treated with either
luciferase or pooled Ctnnb1 siRNA reagent for 24 h prior to additional 24 h incubation with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml). Total
and soluble b-catenin and Hsp70 were detected as described in Fig. 4 legend. (B–D) Quantitative PCR analysis of Axin2, Ahr and CXCR6 expression by
C57MG cells after 24 h incubation with luciferase or pooled Ctnnb1 siRNA reagent followed by 24 h treatment with BSA or Rspo2 plus Wnt3a
[experiment performed in parallel with (A), using the same reagent concentrations]. Results are means +/2 S.D. of triplicate measurements from one
of three representative experiments.
doi:10.1371/journal.pone.0029455.g005
Figure 6. Time-course of Rspo2- and Wnt3a-dependent gene down-regulation in C57MG cells. Quantitative PCR analysis of specific gene
expression in response to Rspo2 (100 ng/ml) alone (blue), Wnt3a (100 ng/ml) alone (green) or the two together (red) at the indicated time points.
Data are the means +/2 S.D. (error bars, sometimes too small to be seen) of triplicate measurements from one of several experiments with similar
results.
doi:10.1371/journal.pone.0029455.g006
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Anti-b-catenin antibody (cat. no. 610154) was from BD Biosci-
ences (San Jose, CA). Anti-LRP6 (cat. no. 2560) and anti-
phospho-LRP6 (Ser1490; also recognizes pLRP5) (cat. no. 2568)
antibodies were from Cell Signaling Technology (Danvers, MA).
Anti-LRP5 (cat. no. 365400) was from Invitrogen (Carlsbad, CA).
Anti-Klf5 (cat. no. ab24331) and Anti-Ahr (cat. no. ab2770) were
purchased from Abcam (Cambridge, MA). Antibody against heat
shock protein-70 (Hsp70, sc-7298) was from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell culture
C57MG mouse mammary epithelial cells [41], a gift from the
Varmus lab, were cultured in DMEM (cat. no. 11995, Invitrogen)
supplemented with 10% fetal bovine serum and 10 mg/ml insulin
(cat. no. 12585-014, Invitrogen) and incubated in 5% CO2 at
37uC.
Microarray analysis
C57MG cells were seeded in 6-well plates (2.5610
5 cells/well).
After an overnight incubation growth medium was replaced with
DMEM lacking supplements, and cells were treated for 24 h with
recombinant mouse Wnt3a (100 ng/ml) or recombinant human
Rspo2 (100 ng/ml) alone or in combination. For the vehicle
control, cells were treated with BSA (16 mg/ml) (cat. no. 81-068-3,
Millipore, Kankakee, IL). Each treatment group was prepared in
triplicate. Cells were harvested in PBS and snap-frozen on dry ice.
RNA isolation, microarray data generation and data analysis
were performed by GenUs Biosystems, Northbrook IL. Total
RNA was extracted using Ribopure RNA isolation kit from
Ambion (Invitrogen). RNA integrity and quality were assessed
using an Agilent Bioanalyzer G2938B with the RNA6000 Nano
Lab Chip (Agilent Technologies, Santa Clara, CA). Alexa-555-
labeled cRNA was prepared by linear amplification of the poly(A)+
RNA population within the total RNA sample. Briefly, 1 mgo f
total RNA was reverse transcribed after priming with a DNA
oligonucleotide containing the T7 RNA polymerase promoter 59
to a d(T)24 sequence. After second-strand cDNA synthesis and
purification of double-stranded cDNA, in vitro transcription was
performed using T7 RNA polymerase. The quantity and quality of
the cRNA was determined by spectrophotometry and with an
Agilent 2100 Bioanalyzer. One mg of purified cRNA was
fragmented to uniform size and applied to Mouse Whole Genome
4644 k arrays (Design ID no. 014868; Agilent Technologies) in
hybridization buffer. Arrays were hybridized at 37uC for 18 h in a
rotating incubator, washed, and scanned with a G2565 Micro-
array Scanner (Agilent Technologies). Arrays were processed with
Agilent Feature Extraction v9.5.3.1 software and data were
analyzed with GeneSpring GX v7.3.1 software (both Agilent
Technologies). Raw and normalized data can be accessed in Gene
Expression Omnibus, consistent with MIAME guidelines (www.
ncbi.nlm.nih.gov/geo/; accession number GSE32096). To com-
pare individual expression values across arrays, raw intensity data
from each gene was normalized to the 75
th percentile intensity of
each array. Only genes with values greater than background
intensity in all replicates of at least one condition were used for
further analysis. Volcano plots were used to filter for differentially
expressed genes .2 fold and p-values,0.05. P-values were
calculated using a two-sample T-test assuming unequal variance.
Quantitative real-time RT-PCR (qRT-PCR)
Cells were seeded in 6-well plates (2.5610
5 or 5610
5 cells per
well) and incubated for 24 h. Growth medium was replaced with
DMEM lacking supplements 30 min prior to treatment with BSA
(16 mg/ml), Wnt3a (100 ng/ml), Rspo2 (100 ng/ml) or Rspo2 (10
or 100 ng/ml) and Wnt3a (100 ng/ml) for the indicated times. In
experiments involving Dkk1, cells were incubated with Dkk1
(1 mg/ml) for 20 min at 37uC prior to the addition of other
proteins.
Figure 7. Contrasting effects of Dkk1 and b-catenin knockdown on representative genes down-regulated by Rspo2 and Wnt3a. (A)
Quantitative RT-PCR analysis of Angpt1 and CCL7 expression following 24 h incubation with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml), with or
without Dkk1 (1 mg/ml) pre-treatment. (B) Quantitative RT-PCR analysis of Angpt1 and CCL7 expression following 24 h incubation with BSA or Rspo2
(10 ng/ml) plus Wnt3a (100 ng/ml) after pre-treatment with siLuc vs. siCtnnb1. Results in (A) and (B) are means +/2 S.D. of triplicate measurements
from one of three representative experiments performed simultaneously with experiments illustrated in Figures 4 and 5.
doi:10.1371/journal.pone.0029455.g007
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with DNase I (cat. no. 18068-015, Invitrogen) for 15 min at room
temperature followed by incubation with 2.5 mM EDTA for
10 min at 65uC to eliminate contamination by genomic DNA. Co-
application reverse transcription was carried out as described
previously [76] with the SuperScript III First-Strand Synthesis
System for RT-PCR (cat. no. 18080-051, Invitrogen). Primers for
qRT-PCR (Table S5) were designed using Primer3 software
(http://frodo.wi.mit.edu/primer3/). The specificity of each prim-
er pair was analyzed by agarose gel elecrophoresis and confirmed
by a single band with the appropriate size. The qRT-PCR was
performed with Brilliant SYBR Green QPCR Master Mix (cat.
no. 600548, Agilent Technologies). For each reaction 80 ng
cDNA and 2 mlo f1 0mM primer set were combined with 26
master mix to a final volume of 20 ml. The reactions were analyzed
in triplicate using the Mx3005P QPCR machine (Agilent
Technologies) with the following settings: 10 min incubation at
95uC followed by a three-step cycling program with 40 cycles of
30 sec at 95uC, 60 sec at 60uC and 30 sec at 72uC. To verify the
specificity of the reaction a dissociation program was run following
the manufacturer’s protocol. Quantification of 18S-RNA and/or
b-actin in each cDNA sample was done to normalize the results.
Data analysis was performed with MxPro software.
siRNA transfection
C57MG cells were transfected with the Neon Transfection
System (Invitrogen) according to the manufacturer’s protocol.
Briefly, 10
6 cells were placed in 100 ml resuspension buffer and
combined with 200 pmol siRNA. Double-stranded short interfer-
ing RNAs targeting mouse b-catenin (cat. no. GS12387) were
purchased from Qiagen (Valencia, CA). In some experiments we
used individual siRNA reagents from this pool (cat. no
SI00942039 and SI00942046). Luciferase (Luc) siRNA (target
sequence: CGUACGCGGAAUACUUCGA) was synthesized by
Dharmacon (Thermo Scientific). Electroporation was carried out
with two pulses having a width range of 20 ms and 1400 V. After
transfection cells were resuspended in 500 ml growth medium and
divided into three wells of a 6-well-plate, each containing 2 ml
growth medium. Then cells were cultured for 24 h, followed by
addition of recombinant proteins and incubation for another 24 h.
Immunoblotting
Treatment conditions were the same as described above (see
RNA isolation and reverse transcription). After incubation with
recombinant proteins cells were washed twice with phosphate
buffered saline (PBS) and lysed with buffer containing 50 mM
HEPES, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100
and protease inhibitor cocktail (cat. no. 04693124001, Roche
Diagnostics, Indianapolis, IN). The cell lysates were clarified by a
centrifugation at 20,8006g for 10 min at 4uC. For SDS-PAGE of
cell lysates, protein concentration was determined with a Bio-Rad
protein assay reagent (Bio-Rad Laboratories, Hercules, CA), and
30 mg protein was loaded per lane. Depending on size of protein a
4–20% or 10% SDS-polyacrylamide Tris-HCl gel (Criterion
Precast Gel; Bio-Rad Laboratories) was used. Proteins were
transferred to Immobilon-P membranes (Millipore) that were
blocked with 5% nonfat dried milk dissolved in TTBS (20 mM
Tris-HCl, pH 8.0, 0.05% Tween 20, 150 mM NaCl), incubated
with primary antibody overnight at 4uC, and subsequently
incubated with horseradish peroxidase-labeled secondary anti-
body. The proteins were visualized with SuperSignal Pico or
Femto chemiluminescent reagents (Thermo Scientific) using
BioMax films (Eastman Kodak Co., Rochester, NY). For detection
of soluble b-catenin, a glutathione S-transferase/E-cadherin pull-
down protocol was followed as previously described [77].
Supporting Information
Table S1 Gene enrichment within gene ontology classifications
following treatment of C57MG cells with Rspo2 and Wnt3a.
(XLS)
Table S2 qRT-PCR analysis of gene expression in C57MG cells
treated with Rspo2 and Wnt3a alone or combined.
(XLS)
Table S3 Dkk1 inhibition of gene expression in C57MG cells
treated with Rspo2 and Wnt3a.
(XLS)
Table S4 siRNA regulation of gene expression in C57MG cells
treated with Rspo2 and Wnt3a or BSA alone.
(XLS)
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